Compare AbCellera Biologics Inc (ABCL) vs Ecolab Inc. (ECL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Ecolab Inc. — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while Ecolab Inc. trades at $274.62 (market cap $79.67B). The key difference: Ecolab Inc. is far larger — about 33.9× AbCellera Biologics Inc's market cap, and Ecolab Inc. pays a 1.03% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ECL | |
|---|---|---|
Market Cap | $2.35B | $79.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $308.35 |
52-Week Low | $2.78 | $245.73 |
Enterprise Value | $1.99B | $88.42B |
Dividend Yield | — | 1.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ECL trades at $283.08, down 0.1% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 EPS of $1.70, meeting expectations, and maintains strong profitability with a net income margin of 12.8%. Recent acquisition of CoolIT for $4.75B enhances its AI cooling portfolio, positioning for long-term growth. Cash flow from operations remains robust at $3.0B in 2025, though net cash flow turned negative due to significant investing activities.
Outlook is positive with 73% analyst buy ratings and a consensus price target of $326.17, implying 15% upside. Risks include rising costs and integration challenges from acquisitions. The stock's high P/E of 38.39 suggests premium valuation, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
